Saturday 17 October 2026
Export ALVO’s income statement to Excel — free account
Alvotech
ALVO Healthcare Drug Manufacturers Specialty & Generic
Alvotech’s revenue for fiscal 2025 (year ended December 2025) was $586.3 million, up 19.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,311.0%, EPS fell 99.5%, free cash flow fell 496.6% and total debt rose 16.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
5.00
0.31
−5.84%
Follow ALVO
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | — | — |
+8 more quarters Free account |
P/S ratio |
— | 3.44 | — | — | |
P/FCF ratio |
— | 0.00 | — | — | |
P/Operating CF |
— | (16.70) | — | — | |
P/B ratio |
— | 0.00 | — | — | |
Price to Tangible BV |
— | 0.00 | — | — | |
EV/Sales |
— | 7.69 | — | — | |
EV/EBITDA |
— | 0.00 | — | — | |
EV/Operating CF |
— | 109.59 | — | — | |
EV/FCF |
— | (14.28) | — | — | |
Quick Ratio |
0.57 | 0.43 | 0.80 | 0.34 | |
Current Ratio |
1.65 | 1.76 | 1.89 | 1.42 | |
Net Debt/EBITDA |
0.00 | 62.41 | 0.00 | 0.00 | |
Debt/Assets |
82.27% | 92.15% | 87.36% | 79.79% | |
Debt/Equity |
(6.82) | (4.64) | (4.57) | (6.36) | |
Asset Turnover |
0.00 | 0.22 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | (58.67) | — | 0.00 | |
Capex/Depreciation |
(4.33) | (4.49) | — | (2.93) | |
Interest Coverage |
— | 0.24 | — | — | |
Research and Development Expense of Revenue |
— | 23.15% | — | — | |
Selling, General and Administrative Expense of Revenue |
— | 24.25% | — | — | |
Intangible Assets out of Total Assets |
0.10 | 0.09 | 0.06 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 2.21% | — | 0.00% | |
Graham Net Nets |
— | (1.24) | — | — | |
Graham Number |
— | 5.08 | — | — | |
Earnings Yield |
— | (34.88%) | — | — | |
Free Cash Flow Yield |
— | (15.65%) | — | — | |
Revenue per Share |
— | 0.36 | — | — | |
Operating CF per Share |
0.00 | (0.21) | — | 0.00 | |
Capex per Share |
0.00 | (0.16) | — | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.36) | — | 0.00 | |
Cash per Share |
0.00 | 0.22 | 0.00 | 0.00 | |
Shareholders Equity per Share |
0.00 | (0.96) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | (0.96) | 0.00 | 0.00 | |
Free Cash Flow |
(64.56) | (106.62) | — | (67.65) | |
Working Capital |
213.79 | 196.20 | 269.94 | 127.94 | |
Capital Expenditures |
(44.77) | (46.19) | — | (80.36) | |
Net Current Asset Value |
(1,233.98) | (1,247.50) | (1,197.57) | (1,153.93) | |
EV/EBIT |
— | 0.00 | — | — | |
Capex to Sales |
0.00 | 0.44 | — | 0.00 | |
Price to Operating Income |
— | 0.00 | — | — | |
| Other line items | |||||
Average Receivables |
77.52 | 108.49 | 115.26 | 68.38 | |
Average Payables |
108.72 | 82.88 | 96.63 | 74.67 | |
Average Inventory |
191.02 | 185.05 | 173.97 | 166.37 | |
Average Assets |
1,490.11 | 1,333.32 | 1,354.25 | 1,321.06 | |
Average Common Equity |
(182.40) | (292.30) | (348.63) | (260.23) |
Columns are period end dates